Report cover image

The World Market for Personalized Medicine Tests for Cancer

Published Jan 19, 2017
Length 140 Pages
SKU # KLI15230306

Description

The World Market for Personalized Medicine Tests for Cancer

This report, Personalized Medicine Tests for Cancer, provides an authoritative look at the market for companion and personalized medicine testing for cancer. The report includes a market size and forecast for personalized medicine testing by geography (US, EU, ROW). Company profiles are included and products are identified by status (on the market, in development)

Table of Contents

140 Pages
    • The Scourge of Cancer
    • Definitions of Companion Diagnostics and Cancer Diagnostics
    • Types of Tests Included
    • Marketing Personalized Medicine-Based Cancer Tests
    • Market
    • Point of View
    • Cancer Treatments
    • Cancer Risk Assessment
    • Cancer Screening
    • Cancer Monitoring
    • Prognosis Assessment
    • Technologies Used
    • Test Targets
    • Products on the Market
    • 20/20 GeneSystems, Inc.
    • Abbott Laboratories
    • ACT Genomics Co., Ltd.
    • Adaptive Biotechnologies Corporation
    • Admera Health (A GENEWIZ Company)
    • Agena Bioscience Inc.
    • Agendia NV
    • Amoy Diagnostics Co., Ltd.
    • ARKRAY, Inc.
    • Biocartis
    • bioMérieux SA
    • Cepheid (Danaher)
    • Genomic Health, Inc.
    • Genoptix (A Novartis Company)
    • Luminex Corporation
    • Myriad Genetics, Inc.
    • Qiagen N.V.
    • QuanDx Inc.
    • Quest Diagnostics
    • Qvella Corporation
    • RiboMed Biotechnologies, Inc.
    • Roche
    • Siemens Healthcare
    • Symbiodx
    • Theranostics Health Inc. (Acquired by Avant Diagnostics, Inc.)
    • Thermo Fisher Scientific, Inc.
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.